Inspire Medical Systems Inc, a medical technology company that makes an implantable therapy for obstructive sleep apnea (OSA) and is focused on the development and commercialization of minimally invasive solutions for patients with the sleep disorder, reports that the Blue Cross Blue Shield Association’s (BCBSA) Evidence Street issued a positive assessment of Inspire therapy to its members. BCBSA is a national federation of 36 Blue Cross and Blue Shield (BCBS) companies.
The report summarized that sufficient evidence exists to determine that hypoglossal nerve stimulation results in a meaningful improvement in the net health outcome for patients meeting the following selection criteria, which are based on information from clinical study populations and clinical expert opinion:
- age ≥ 22 years in adults, or adolescents with Down’s syndrome (age 10 to 21 years); and
- diagnosed moderate to severe OSA (with less than 25% central apneas); and
- CPAP failure or inability to tolerate CPAP; and
- body mass index ≤ 35 kg/m2 in adults; and
- favorable pattern of palatal collapse.
“This positive assessment demonstrates the strength of the clinical evidence for Inspire therapy and is…